Close Menu

NEW YORK – SkylineDx said Tuesday it has entered an agreement with BioInvent International to characterize gene expression and immunological signatures in the tumors of patients before and after they have been treated with BI-1206, BioInvent's lead therapy candidate for patients with non-Hodgkin lymphoma and solid cancers.

The companies will research and develop predictive immunological signatures to help identify patients who are likely to show clinical responses if treated with BI-1206, Rotterdam, Netherlands-based Skyline Dx said.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.